Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Bought by Knights of Columbus Asset Advisors LLC

Knights of Columbus Asset Advisors LLC raised its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 99.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 185,845 shares of the biopharmaceutical company’s stock after acquiring an additional 92,552 shares during the quarter. Knights of Columbus Asset Advisors LLC owned approximately 0.14% of Halozyme Therapeutics worth $6,869,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Harbour Investments Inc. purchased a new position in shares of Halozyme Therapeutics in the 4th quarter valued at about $51,000. Advisory Services Network LLC boosted its stake in shares of Halozyme Therapeutics by 50.5% in the 1st quarter. Advisory Services Network LLC now owns 903 shares of the biopharmaceutical company’s stock valued at $34,000 after buying an additional 303 shares during the period. Belpointe Asset Management LLC boosted its stake in shares of Halozyme Therapeutics by 42.0% in the 1st quarter. Belpointe Asset Management LLC now owns 1,238 shares of the biopharmaceutical company’s stock valued at $47,000 after buying an additional 366 shares during the period. Acadian Asset Management LLC purchased a new position in shares of Halozyme Therapeutics in the 1st quarter valued at about $92,000. Finally, BOKF NA purchased a new position in shares of Halozyme Therapeutics in the 4th quarter valued at about $201,000. 97.79% of the stock is owned by institutional investors and hedge funds.

Halozyme Therapeutics Trading Up 0.9 %

NASDAQ HALO traded up $0.33 during trading hours on Friday, hitting $38.14. 291,710 shares of the company’s stock were exchanged, compared to its average volume of 1,258,643. The business’s 50 day moving average is $39.50 and its 200-day moving average is $37.76. Halozyme Therapeutics, Inc. has a 12-month low of $29.85 and a 12-month high of $45.00. The firm has a market capitalization of $4.85 billion, a P/E ratio of 17.92, a price-to-earnings-growth ratio of 0.44 and a beta of 1.25. The company has a debt-to-equity ratio of 17.89, a quick ratio of 5.50 and a current ratio of 6.64.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Tuesday, February 20th. The biopharmaceutical company reported $0.75 EPS for the quarter, missing the consensus estimate of $0.77 by ($0.02). The firm had revenue of $230.04 million for the quarter, compared to analyst estimates of $235.25 million. Halozyme Therapeutics had a return on equity of 248.20% and a net margin of 33.96%. As a group, analysts anticipate that Halozyme Therapeutics, Inc. will post 3.45 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, SVP Michael J. Labarre sold 10,000 shares of the stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $41.64, for a total value of $416,400.00. Following the completion of the sale, the senior vice president now owns 156,558 shares in the company, valued at $6,519,075.12. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders sold 30,000 shares of company stock worth $1,196,800 over the last three months. 2.40% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on HALO shares. JMP Securities reiterated a “market outperform” rating and issued a $72.00 price objective on shares of Halozyme Therapeutics in a research note on Wednesday, February 21st. TD Cowen began coverage on Halozyme Therapeutics in a research note on Thursday, February 29th. They set an “outperform” rating and a $54.00 target price for the company. The Goldman Sachs Group decreased their target price on Halozyme Therapeutics from $45.00 to $40.00 and set a “neutral” rating for the company in a research note on Thursday, January 18th. Morgan Stanley decreased their target price on Halozyme Therapeutics from $61.00 to $59.00 and set an “overweight” rating for the company in a research note on Tuesday, December 26th. Finally, StockNews.com upgraded Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, February 23rd. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $53.29.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.